Drug Trial Radar · NCT02796677
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
Last checked: Nov 19, 2026Latest source record: Nov 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,595
Actual
Start
Jul 5, 2016
Primary completion
Jun 8, 2017
Study completion Jun 8, 2017
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared to individual components and TIO (Tiotropium) 18 μg when administered to patients with stable chronic obstructive pulmonary disease (COPD).
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)Drug
Inhalation powder
Aclidinium bromide 400 μg (AB 400 μg)Drug
Inhalation powder
Formoterol fumarate 12 μg (FF 12 μg)Drug
Inhalation powder
Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μgOther
Inhalation powder
Tiotropium 18 μg (TIO 18 μg)Drug
Powder in capsules for oral inhalation
Placebo to TIO 18 μgOther
Powder in capsules for oral inhalation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 24Time frame: At baseline 1-hour postdose and Week 24
- Change From Baseline in Morning Predose (Trough) FEV1 of AB/FF 400/12 μg Compared to FF 12 μg at Week 24Time frame: At baseline morning predose and Week 24
- Change From Baseline in Morning Predose (Trough) FEV1 at Week 24 Comparing AB 400 μg Versus TIO 18 μg to Demonstrate Non-inferiorityTime frame: At baseline morning predose and Week 24
Locations
163 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Gulf Shores, Alabama
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Corona, California
Research Site
Fresno, California
Research Site
Fullerton, California
Research Site
Lincoln, California
Research Site
San Diego, California
Research Site
Waterbury, Connecticut
Research Site
Clearwater, Florida
Research Site
Edgewater, Florida
Research Site
Hollywood, Florida
Research Site
Homestead, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami Lakes, Florida
Research Site
Ormond Beach, Florida
Research Site
Port Orange, Florida
Research Site
Sarasota, Florida
Research Site
St. Petersburg, Florida
Research Site
St. Petersburg, Florida
Research Site
Tampa, Florida
Research Site
Winter Park, Florida
Research Site
Blue Ridge, Georgia
Research Site
Woodstock, Georgia
Research Site
Chicago, Illinois
Research Site
Portage, Indiana
Research Site
Lafayette, Louisiana
Research Site
Fall River, Massachusetts
Research Site
Chelsea, Michigan
Research Site
Farmington Hills, Michigan
Research Site
Troy, Michigan
Research Site
Edina, Minnesota
Research Site
Fridley, Minnesota
Research Site
Minneapolis, Minnesota
Research Site
Woodbury, Minnesota
Research Site
Saint Charles, Missouri
Research Site
St Louis, Missouri
Research Site
St Louis, Missouri
Research Site
Fremont, Nebraska
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.